bioRxiv Science⌕ Search

Biology subjects

Xu, J.-Y.

Publications and source records attributed to Xu, J.-Y..

2 recordsLinked to original sources

DGMP: Identifying Cancer Driver Genes by Jointing DGCN and MLP from Multi-omics Genomic Data

Identification of cancer driver genes plays an important role in precision oncology research, which is helpful to understand the cancer initiation and progression. However, most of existing computational methods mainly used the protein-protein interaction networks (PPIs), or treated the directed gene regulatory networks (GRNs) as the undirected gene-gene association networks to identify the cancer driver genes, which will lose the unique structure regulatory information in the directed GRNs, and then affect the outcome of the cancer driver genes identification. Here, based on the multi-omics pan-cancer data (i.e., gene expression, mutation, copy number variation and DNA methylation), we proposed a novel method (called DGMP) to identify cancer driver genes by jointing Directed Graph Convolution Network (DGCN) and Multilayer Perceptron (MLP). DGMP learns the multi-omics features of genes as well as the topological structure features in GRN with DGCN model, and uses MLP to weight more on gene features for mitigating the bias toward the graph topological features in DGCN learning process. The results on three gene regulation networks show that DGMP outperforms other existing state-of-the-art methods. It can not only identify highly mutated cancer driver genes but also the driver genes harboring other kinds of alterations (e.g., differential expression, aberrant DNA methylation) or genes involved in GRNs with other cancer genes. The source code of DGMP can be freely downloaded from https://github.com/NWPU-903PR/DGMP.

bioinformatics↗

Integration of gut microbiome, host biomarkers, and urine metabolome data reveals networks of interactions associated with distinct clinical phenotypes

BackgroundComprehensive analyses of multi-omics data may provide insights into interactions between different biological layers in relation to distinct clinical features. Here we integrated data on the gut microbiota, blood parameters and urine metabolites of treatment-naive individuals presenting a wide range of metabolic disease phenotypes to delineate clinically meaningful associations.\n\nResultsTrans-omics correlation networks revealed that candidate gut microbial biomarkers and urine metabolite features covaried with distinct clinical phenotypes. Integration of the gut microbiome, the urine metabolome and the phenome revealed that variations in one of these three systems correlated with changes in the other two. Of specific note in relation to clinical parameters of liver function, we identified Eubacterium eligens, Faecalibacterium prausnitzii and Ruminococcus lactaris to be associated with a healthy liver function, whereas Clostridium bolteae, Tyzzerella nexills, Ruminococcus gnavus, Blautia hansenii, and Atopobium parvulum were associated with blood biomarkers for liver diseases. Variations in these microbiota features paralleled changes in specific urine metabolites. Network modeling yielded two core clusters including one large gut microbe-urine metabolite close-knit cluster and one triangular cluster composed of a gut microbe-blood-urine network, demonstrating close inter-system crosstalk especially between the gut microbiome and the urine metabolome.\n\nConclusionsDistinct clinical phenotypes are manifested in both the gut microbiome and the urine metabolome, and inter-domain connectivity takes the form of high-dimensional networks. Such networks may further our understanding of complex biological systems, and may provide a basis for identifying biomarkers for diseases.

microbiology↗